Title:

Development and Validation of the Cannabis Exposure in Pregnancy Tool (CEPT)

Kathleen H. Chaput PhD[1,2], Carly A. McMorris PhD[3], Amy Metcalfe PhD[1,2] Catherine Ringham PhD, Stephen Wood MD[1], Deborah McNeil PhD[2,5], Sheila W. McDonald PhD[2,6]

1. Department of Obstetrics and Gynecology, Cumming School of Medicine, University of Calgary
2. Department of Community Health Sciences, Cumming School of Medicine University of Calgary
3. Werklund School of Education, School and Child Psychology, University of Calgary
5. Maternal Newborn Child and youth Strategic Clinical Network, Alberta Health Services
6. Research and Innovation Population, Public, and Indigenous Health, Alberta Health Services

Correspondence:

Kathleen H. Chaput
1403 29 Street NW
Calgary, Alberta, T2N 2T9
Phone: 1-403-944-4009; email:khchaput@ucalgary.ca

Funding statement: This project was funded by a competitive research grant from the Alberta Children's Hospital Research Institute, University of Calgary.

Competing interests: No Authors have competing interests to declare.

Word count: 2868

Abstract: (250 words)

Background: Evidence of the associations between prenatal cannabis exposure and maternal, infant, and child health outcomes remains conflicting amid broad legalization of cannabis across Canada and 40 American states. A primary critical limitation of existing evidence lies in the non-standardized and crude measurement of prenatal cannabis exposure, resulting in high risk of misclassification bias. We developed a standardized tool to comprehensively measure prenatal cannabis use in pregnant populations for research purposes.

Methods: We conducted a patient-oriented tool development and validation study using a six-step, bias-minimizing process. Following an environmental scan and critical appraisal of existing prenatal substance use tools, we recruited pregnant past- present- and non-cannabis users via targeted social media advertising and obstetric clinics in Alberta, Canada. We conducted individual in-depth interviews and cognitive interviewing in separate sub-samples, to develop and refine our tool. We assessed content, convergent and discriminant validity, internal consistency and 3-month test-retest reliability, and validated externally against urine THC bioassay at multiple timepoints in pregnancy.

Results: 194 pregnant women participated. The 9-item Cannabis Exposure in Pregnancy Tool (CEPT) had excellent discriminant (Cohen's kappa=-0.27 to 0.15) and convergent (Cohen's kappa=0.72 to 1.0) validity; as well as high internal consistency (Chronbach's alpha = 0.92), and very good test-retest reliability (weighted Kappa=0.92, 95% C.I. [0.86 – 0.97]). The CEPT is valid against gold-standard urine THC bioassay (sensitivity 77%, specificity 100%) in preliminary analyses.

Interpretation: Developed for research purposes, the CEPT is a novel, valid and reliable measure of frequency, timing, dose, and mode of prenatal cannabis exposure, in a contemporary sample of pregnant women. Use of the CEPT can improve measurement accuracy, and thus the quality of research examining associations between antenatal cannabis use and maternal and child health outcomes.

53 **Background:**

54 Following cannabis legalization in Canada, prenatal cannabis use is rising (1,2). Despite recent
55 studies of prenatal cannabis use and adverse maternal, infant, and child outcomes (3–6), the
56 evidence remains conflicting (7–12). A critical limitation of published studies is a high risk of
57 misclassification bias, resulting from a lack of standardized measurement of cannabis exposure
58 across adequate domains, including frequency, dose, modes, timing of use in pregnancy, and
59 second-hand smoke and vapour. Canadian and United States (US) governments highlight an
60 urgent need for high-quality cannabis-related health research and endorse pregnant individuals
61 and infants as priority populations (9,10,13). Improved options for measuring prenatal cannabis
62 use are a key component to improving the quality of the evidence.

63

64 Current prenatal cannabis-use measurement options available for research include
65 administrative data collected during routine prenatal care, substance use disorder (SUD)
66 screening tools, non-validated questionnaires, and biological tests. Administrative data is
67 problematic because pregnant people are known to conceal or under-report prenatal substance
68 use to physicians (14,15). Further, cannabis use screening is not standardized practice, occurs
69 variably, and is seen as low-priority for the majority of obstetricians (16). While Canadian
70 studies using administrative data have reported prenatal cannabis-use prevalence between 2%
71 and 3% (2–4), emerging evidence from an *anonymous* population-based survey indicates 11%
72 prevalence of prenatal cannabis use (17), and in a US study only 36% of women with cannabis-
73 positive urine tests had reported their use to a care provider (18), indicating that the majority
74 of prenatal cannabis users may be misclassified in administrative data studies.

75 While self-administered research questionnaires have proven to garner more accurate
76 reporting of substance (e.g. alcohol) use in pregnancy than screening in clinical settings (19,20),
77 non-standardized survey questions have limited utility for measurement of prenatal cannabis
78 use, as they can unintentionally convey perceived bias against prenatal cannabis use. They
79 often identify cannabis as an illicit drug and do not differentiate between medicinal and
80 recreational use, which contradicts social perception and may increase response bias (18,21).
81 Survey questions are problematic for studying nuanced associations with maternal and infant
82 health outcomes due to inconsistent assessment of frequency and timing of use, including
83 changing patterns through pregnancy, and often lack dose measurement, or use subjective
84 dose-terminology (9,10,22–28). Further, most lack measurement of potentially important
85 consumption modes aside from smoking (vapourized, edible, topical, second-hand)(22–24).
86 Standardized SUD screening tools aim to detect a diagnosable SUD, and do not measure
87 patterns of consumption of specific substances like cannabis throughout pregnancy (29). Many
88 screen for alcohol misuse alone (30–33), or combine all drugs into a single category (29)
89 preventing the separate evaluation of cannabis-related health outcomes. While biological
90 (urine/blood/saliva) cannabis-screeners exist they are limited to detection within 1-5 weeks of
91 use, depending on individual metabolism and test cut-off levels (34–38). Biological samples are
92 also resource-intensive and stigmatizing to collect, limiting their utility for prospective research.
93 Our study developed and validated a novel prenatal cannabis use measurement tool,
94 that addresses the limitations of current measurement methods, and uses a patient-oriented
95 approach in order to identify patient-perceived stigma, and methods of reducing perceptions of
96 stigma and other sources of response bias, using a six-step, peer-reviewed process (39).

97 **Methods:**

98 We recruited pregnant, past- and current-cannabis users and non-users, <36 weeks' gestation,
99 between 08/2019 and 04/2020 for this mixed-methods tool development and validation study.
100 We used social media advertising targeted to women aged 18-45, residing in Alberta, with listed
101 interests or group memberships related to pregnancy, parenting, and/or cannabis, and posted
102 gender-neutral recruitment ads in an online trans-gender parent support group. Study
103 recruitment letters were also mailed to patients who visited Alberta Health Services (AHS)
104 clinics for pregnancy-related care in the preceding six months, identified using pregnancy-
105 related codes in the National Ambulatory Care Reporting System (NACRS)(Appendix A). Our
106 target sample size of 150 participants was sufficient to detect a Cronbach's alpha of ≥0.9, with
107 95% confidence for test-retest reliability on a tool that contains up to 15 items (39). This study
108 was approved by the Conjoint Health Research Ethics Board at the University of Calgary (REB19-
109 0670), and Written informed consent was obtained from all participants.

110

111 *Step 1 Qualitative Interviews:* A crucial step often overlooked in tool development is the use of
112 qualitative methods to provide patient perspective, and ensure appropriate wording and
113 response options (49). We conducted *individual in-depth interviews* (IDIs) with 10 participants
114 purposively selected from the full sample, to represent regular and occasional cannabis users,
115 and non-users (Figure 1). Two female research assistants with training in qualitative
116 interviewing conducted telephone interviews at a time chosen by the participant about
117 participant views and experiences with cannabis use in general, and during pregnancy. Prior to
118 IDIs, participants had two points of contact with research staff to discuss study details,

119 questions, concerns, and confidentiality. Research assistants then established a trusting
120 relationship, by disclosing their own connections to the study topic, emphasizing a non-
121 judgmental approach, acknowledging that all experiences shared were important, and
122 guaranteeing privacy of information. We recorded and transcribed interviews verbatim, and
123 used deductive thematic analysis to extract pre-determined themes of: language around
124 cannabis and its use; perceptions of stigma and judgement, and their relations to truthful
125 disclosure of use; patterns of use in pregnancy (timing, frequency of use, typical dose);
126 motivations for use; and forms of cannabis used in the qualitative transcripts. Two team
127 members experienced in qualitative methods coded salient content that corresponded to the
128 pre-determined themes, and then collapsing codes into broader themes using constant
129 comparison technique, discussion and consensus. Themes were then reported back to the
130 qualitative participants via email for member-checking of the relevance and appropriateness of
131 the qualitative findings to ensure truth value.
132 *Step 2 Devising Items:* We devised items, including wording, to form the initial tool based on
133 strengths and shortcomings identified in existing SUD tools and published survey questions
134 (Table 1), and on themes identified from IDIs to form a draft tool. We eliminated double-
135 barreled questions, ambiguous wording and ensured a 6th grade reading level.
136 *Step 3 Cognitive interviewing and bias reduction:* Schwartz and Oyserman(40) propose five
137 stages of cognition required to accurately self-report behaviour, each of which are susceptible
138 to bias: 1. question understanding, 2. recalling relevant behaviour, 3. inference & estimation, 4.
139 mapping answer onto response options, and 5. answer editing. In order to identify points of
140 bias at all five stages of cognition, we then contacted an additional sub-sample of participants

141 from the full sample, and conducted individual *cognitive interviews,* in which respondents were
142 asked to think aloud, and share impressions, understanding and reasoning related to each of
143 the five stages of cognition, as we administered the newly developed tool.(41) We iteratively
144 revised items according to each participant's feedback prior to each subsequent interview. This
145 process was repeated until no new suggestions for revision were made in two consecutive
146 interviews. This occurred after the 17th cognitive interview.
147 *Step 4 Face and Content Validation:* We then formatted the refined items into the CEPT online
148 tool and sent it to a panel of experts in epidemiology, addictions, obstetrics, neonatology,
149 pediatrics and neurodevelopment with research and clinical interests in prenatal substance
150 exposure and child health, identified using and environmental scan and from our team's
151 professional networks. They were asked to assess whether the tool adequately captured all
152 domains of measurement that are critical to prospective research on the associations between
153 prenatal cannabis use and maternal and infant health.
154 Step 5 Covergent and Discriminant Validation: We then administered the finalized CEPT, along
155 with the SURP-P(42) and 4Ps+ (30) SUD screening tools via electronic questionnaire, to our
156 remaining sample of 150 women. Because biological tests are only able to accurately indicate
157 cannabis exposure for short time periods, and their reliability is dependent on dose of
158 exposure, there is no true gold-standard measure of the patterns of cannabis consumption
159 throughout pregnancy. We therefore measured concurrent validity of CEPT responses against
160 detailed cannabis use information revealed during the IDIs, using Cohen's kappa statistic. There
161 is strong evidence that through rigorous qualitative interview techniques, a trust-relationship
162 can be established between researcher and participant, and a high degree of truth value can be

163 achieved (43). We assessed discriminant validity of CEPT responses against SURP-P and 5Ps
164 tools using Cohen's kappa. We calculated internal consistency on all CEPT cannabis
165 consumption items using Chronbach's alpha, while acknowledging that it is designed to
166 measure multiple constructs of cannabis exposure (i.e. any use, frequency, timing, dose, mode
167 and reasons for consumption), rather than a single construct such as a disease state. However,
168 we anticipated internal consistency among the CEPT items, as a person indicating no
169 consumption on one item should have similar answers on all other items, and those indicating
170 some use should have non-zero responses for dose, mode frequency and reasons for use. We
171 then re-administered the tool to all participants (n=150) 3 months later to assess test-retest
172 reliability (agreement) using a weighted Cohen's kappa.

173 In an additional external sample of 24 pregnant participants, we validated CEPT responses
174 against urine bioassay measurements of 11-nor-9-carboxy-Δ^9- THC, the most abundant THC
175 metabolite. Participants provided urine samples in sterile collection containers that were
176 shipped frozen to our laboratory by pre-paid courier for analysis, within 24hours of completing
177 an online questionnaire containing the CEPT. We stored urine samples in a dedicated -80°c
178 freezer until analysis. 2ml aliquots were taken from thawed samples, diluted (2x) with ultrapure
179 water and assayed in triplicate using a 96-strip-well, THC Metabolite ELISA Kit (catalogue #
180 701570, Cayman Chemicals^{TM}, United States of America) according to manufacturer's protocol.
181 No freeze-thaw cycles were allowed.

182

183 **Results:**

184 Our sample included 175 pregnant past, current, and non-consumers of cannabis. Specific sub-
185 samples participated in various steps (Figure 1). Table 2 summarizes participant characteristics
186 at enrollment. Other sociodemographic characteristics of our sample were similar to the overall
187 maternal population in Canada (44–46). (Fig. 2)
188
189 **Qualitative interviews:**
190 We chose to cease qualitative data collection after completion of 10 interviews as no new ideas
191 were apparent under our deductive themes after analysis of the 8th transcript, indicating that
192 thematic saturation had been reached. Summaries of a-priori deductive themes and illustrative
193 quotes are presented in Table 2. Numerous important insights around bias-minimizing language
194 and wording, tool structure, response options, and patterns of use were gained from qualitative
195 results, and drove the terminology and language used in the tool preamble and questions,
196 guided tool structuring including inclusion of specific items (e.g. reasons for use) and response
197 options, and determined the method of dose measurement. While legalization was perceived
198 to have reduced stigma around cannabis use in general, perceptions of stigma against use in
199 pregnancy were prevalent and thus important for consideration to encourage accurate
200 disclosure. Several participants noted that including a response option to disclose cannabis
201 consumption that occurred only prior to pregnancy recognition was crucial, and noted that for
202 many, if this option was not present, they would not report any use, even if they had consumed
203 some cannabis prior to pregnancy recognition. One of the most challenging aspects of cannabis
204 consumption measurement is identifying dose. IDI results provided insight into a reliable
205 method of quantifying approximate dose per use (i.e. comparing amounts to common objects,

206 like food items or coins). Approximate THC/CBD content can be inferred based on mean THC
207 content of dried cannabis available on the contemporary market (24%)(47), or the labeled
208 concentration of products as reported by participants.(Supplementary file 2)
209
210 **Cognitive interviews:**
211 We completed cognitive interviews with a separate sub-sample of 17 participants to assess and
212 minimize points of bias through participant-led refinement. This resulted in 9 sequential
213 iterations of our initial draft tool. Perceived sources of bias at all five stages of cognition were
214 identified, and we made refinements to minimize the potential for biased responses based on
215 participant feedback, until no further changes were suggested. (Figure 2)
216
217 *Question understanding*: Most of the draft tool questions were well understood; however,
218 some changes were made to improve clarity.
219 *Recalling relevant behaviour*: All participants indicated that they were accurately able to recall
220 details of first-hand cannabis consumption, including frequency, trimester of consumption,
221 reasons, modes, and amounts per use. Nearly all participants (93%) indicated they were able to
222 accurately recall the details of second-hand cannabis smoke or vapour exposure, aside from
223 brief outdoor exposures. We amended the second-hand exposure questions to align with
224 exposure confirmed by previous literature to elevate THC blood-levels of the passive user to
225 equivalent levels in the first-hand user (48).

226 *Inference & estimation:* Participants did not express concerns about inference or estimation on
227 items measuring any consumption/exposure, or frequency, timing or reasons for use. Dose
228 questions were adjusted to address perceived ambiguity and aid with estimation (figure 2).
229 *Mapping answers onto response options:* Several participants noted problems with initial dose-
230 per-use response-options, increments for some product types were deemed too large for use in
231 pregnancy, and we refined categories to align with participant-identified appropriate ranges
232 and increments.
233 *Answer editing:* No participants expressed the need to edit responses once the above
234 clarifications and response-option edits had been made. Further, participants agreed that the
235 overall tool was non-judgemental, appropriate, and acceptable to them as pregnant research
236 participants, and that it would elicit truthful responses, confirming face and content validity
237 from the participant perspective.
238 The final refined CEPT has 9 items measuring weeks of gestation, second-hand exposure,
239 partner use, trimester(s) of consumption, frequency, reasons, modes of consumption, and dose
240 per use for each mode indicated. Frequency, reasons, modes, and dose items repeat for each
241 trimester of use indicated. (Appendix A)
242
243 ***Validity and reliability:***
244 Content validity was deemed high by our expert reviewers, who noted the CEPT's ability to
245 distinguish high, single doses from sustained low dose exposure, and to capture changes in use
246 patterns across all trimesters.

247 Concurrent validity was excellent, with agreement between IDI participant CEPT responses and
248 use reported in IDIs, ranging from 80% to 100%, and kappa values ranging from substantial
249 (0.72) to perfect (1.0) (49) (Table 4). The timing of use construct showed the lowest level of
250 agreement, which was expected. Use will be reported in more trimesters as a pregnancy
251 progresses. A greater proportion of participants (40%) reported third-trimester use on the
252 online CEPT, compared with IDIs (30%), which occurred 5-6 weeks prior. Discriminant validation
253 indicated poor agreement between two pregnancy SUD screening tools (5ps and the SURP-
254 p)(refs), with weighted Kappa values ranging from -0.31 to 0.36 indicating that the CEPT
255 measures different constructs from those on the existing tools. (Table 5)
256
257 Reliability testing showed excellent internal consistency (Chronbach's alpha=0.92) and
258 substantial to near-perfect Kappa values (0.71-0.99) for test-retest reliability (Table 6). Although
259 some patterns of use may be expected to change throughout pregnancy, the strong agreement
260 between early and late pregnancy responses on the CEPT support that recall of cannabis
261 consumption using this tool is reliable up to delivery.
262
263 CEPT-reported cannabis use and/or exposure to second-hand cannabis was valid against urine-
264 THC bioassay in our preliminary analyses (table 5), and show much higher sensitivity (77%) than
265 self-report during prenatal care observed in previous studies (36%), and had 100% specificity,
266 indicating that it has promise as an improved measure of prenatal cannabis use for research
267 purposes.
268

269 **Interpretation:**

270 The CEPT addresses the measurement limitations faced by previously published studies of
271 prenatal cannabis consumption and associated maternal and infant health outcomes, which are
272 highly susceptible to misclassification bias, have inconsistent findings and are rated moderate
273 at best by the US National Academies of Science Engineering and Medicine(10,50). It offers
274 researchers a measurement option with strong validity and reliability, that accounts for
275 frequency of cannabis consumption, reasons for consumption, modes of consumption,
276 estimated dose-per-use, measures CBD and THC, and allows repeated measures per trimester
277 to capture changing patterns of exposure. It also captures frequency and timing of second-hand
278 exposure, in addition to partner's cannabis use. The CEPT thus enables more complete picture
279 of exposure over pregnancy than currently published studies have been able to capture. The
280 patient-oriented methods we used are a strength; qualitative in-depth interviews can reveal
281 aspects of health behaviour that contrast with the underlying assumptions held by researchers
282 that can unintentionally interfere with the five stages of cognition and create opportunities for
283 biased response (39,40). Evidence from studies on the measurement of prenatal alcohol use
284 indicate that non-disclosure bias for prenatal substance use varies according to participant
285 perceptions, and that question wording and structure informed by patient-oriented designs can
286 improve validity.(20,51) Further, the language used, the tone of the questions, and the
287 perceived intent of the tool are all critical components contributing to non-biased response.
288 The qualitative interviews in our study explored in-depth what was perceived as judgemental or
289 stigmatizing, and revealed patient-identified methods for reducing the perception of judgement
290 and stigma in our tool. The cognitive interviews acted to further reduce sources for perceived

291 stigma, thereby reducing the potential for biased responses. While we may never be able to
292 completely eliminate the bias arising from hesitancy to report prenatal cannabis use due to
293 stigma, our patient-oriented development process was chosen specifically because it is crucial
294 for minimising perceived stigma, and ensuring a much lower probability of bias than the
295 methods of measurement used in existing studies, including biological samples, which do not
296 allow the participant to explain their reasons for use, nor to judge the motivations of the
297 researchers for measuring their use of cannabis.
298
299 Although there remains no feasible gold-standard measure of prenatal cannabis consumption,
300 the CEPT represents a useful tool for researchers to augment the quality and expand the scope
301 of longitudinal research into the health outcomes associated with prenatal cannabis exposure.
302 Our results indicate that it has the potential to minimize self-report bias, and its nuanced
303 measurement of multiple dimensions of cannabis consumption may also reduce
304 misclassification of very low exposures, allow for assessment of potential dose-response
305 relationships, and enable the identification of critical windows of fetal exposure in future
306 studies, that were not possible with previous crude measures.
307
308 *Limitations:* The CEPT is designed to measure behaviours over pregnancy, rather than to detect
309 a condition or health state. Where medical screening tools can be validated against diagnostic
310 tests or interviews, validating a measure of behaviour is more complex. A limitation of our
311 study is the lack of a true gold-standard measure of cannabis consumption patterns throughout
312 pregnancy for validation, which would require at least weekly serial urine collection throughout

313 gestation, which was financially infeasible for this study. However, we have preliminarily
314 validated CEPT responses against a biological reference-standard, showing very good sensitivity
315 and excellent specificity. While we could not attain a true biological gold-standard in our study,
316 the validation we conducted against single bioassays, and in-depth qualitative interviews
317 remains a rigorous method. Biological levels of THC metabolite cannot be falsified, and the
318 qualitative methods we employed result in high credibility and truth-value for qualitative
319 results (57). Further, IDIs allowed for comparison of binary cannabis use as well as multiple
320 aspects of cannabis consumption patterns (modes, frequency, timing) that are more difficult
321 with a biological test comparator. Although our study sample was adequate to detect a
322 Cronbach's alpha of $\geq$0.9 on a tool with up to 15 items, we acknowledge that our overall sample
323 and the preliminary bioassay validation sample (n=24) was small. Future validation studies
324 should include larger samples to confirm findings. It is also important to note that our tool and
325 the validation conducted are limited to English-speaking populations, and translations will
326 require further validation. Additionally, cultural differences may impact the interpretations of
327 participants and use in non-Canadian settings should also be validated separately.

328

329 Conclusion:

330 Prenatal cannabis use and its associated health outcomes have been identified as priorities for
331 research in Canada following cannabis legalization.(9) We recommend the CEPT as a rigorous,
332 feasible, patient-oriented health research tool for measuring prenatal cannabis consumption.
333 The use of the CEPT as a standardized measure of prenatal cannabis consumption in future

334 studies can contribute substantial new knowledge about the implications of timing, dose,
335 frequency, and modes of exposure for maternal, fetal, infant and child health, accounting for
336 varying patterns of consumption and the strength and diversity of cannabis products available
337 on the contemporary Canadian market. The CEPT has the potential to significantly improve
338 measurement accuracy and thus the quality of research in this area, which can in turn inform
339 evidence-based education, prevention and health policy to mitigate potential health risks.
340
341 Data sharing: Quantitative data can be made available in accordance with the ethics approval
342 for the study, on reasonable request to the corresponding author.
343

Table 1: Measurement domains of existing prenatal cannabis measurement options

Includes measure of:	**4ps**	**4ps+**	**WIDUS**	**CRAFFT**	**SURP-P**	**StatsCan**	**Generation-R**	**NSDUH**
Cannabis separately	no	no	no	yes	yes	yes	yes	yes
Use in pregnancy	no	yes	no	No	no	no	yes	*indirect
Frequency of use	no	no	no	no	no	yes	yes	yes
Timing of use in pregnancy	no	no	no	no	no	no	1st trimester & pre-preg.	*indirect
Dose	no	no	no	no	no	yes	no	no
Mode of consumption	no	no	no	no	no	yes	no	no
Medicinal vs. recreational use	no	no	no	no	no	yes	no	no
Time-span covered	Past ever	Past month	Past ever	Past 12 months	Past ever	Past 3 months	Pre-pregnancy, First trimester	*Past 3 mos.
Second-hand exposure/partner use	yes	yes	yes	no	yes	no	yes	no
Reference	(56)	(28)	(57)	(58)	(40)	(60)	(61)	(37)

4Ps=Parent drug problem, Partner drug problem, Past use of substance
4Ps+= Parent drug problem, Partner drug problem, Past use of substance, Pregnancy use
*WIDUS= Wayne Indirect Drug Use screener; CRAFFT = Car, Relax, Alone, Forget, Friends, Trouble; SURPP= substance use risk in pregnancy profile; NSDUH = National Survey on Drug Use and Health; StatsCan = Statistics Canada * specific date can be cross-referenced with pregnancy information if provided*

360 Tab

361 le

362 2:

363 Par

364 tici

365 pan

366 t

367 Ch

368 ara

369 cte

370 rist

371 ics

372 at

373 Enr

374 oll

375 me

376 nt

Variable	*Proportion % (n)*	*95% Confidence Interval*	*Mean*	*Range*
Gestational age			27 weeks	8-36 weeks
1st trimester	4	1.9 - 9.2		
2nd trimester	41.5	33.6 - 49.9		
3rd trimester	54.2	45.9 - 62.3		
Parity			1	0-5
nulliparous	37 (63)	29 - 45		
multiparous	63 (107)	54.9 – 70.1		
Maternal Age				
<35	83 (141)	*		
≥35	17 (29)	*		
Female gender	100 (170)			
Ethnicity				
Caucasian	84.1 (23)	77 - 89		
Non-Caucasian	15.9 (121)	11 - 22		
Residence				
Urban	75 (128)	67 – 81		
Rural	25 (42)	19 - 33		
Home ownership				
Owns home	52 (88)	42 - 58		
Rent/other	48 (82)	41 - 57		
Marital Status				
Married or common-law	78 (133)	77 - 79		
other	22 (38)	18 - 26		
Annual Household Income				
< $60,000	59	52 - 67		
$60,000 or more	41	33 - 48		

377 * Only aggregate age category available

378

379

380 Table 3: Deductive themes and illustrative quotes *(n=10)*

Theme 1 - Language/wording: Participants indicated that non-judgemental wording around cannabis use as well as specific terms and context affected their choice to disclose their cannabis use while pregnant.	
	"…say "cannabis" instead of marijuana, because I think of marijuana only being the plant… not edibles, or cbd and lip balm, or whatever."
	"Why you want to know is important. I would be way more up-front if I know it's for research, than like, if they want to know at the hospital…"
	"If someone sounds judgmental, that would make me not want to discuss it. If it's something that it's

	clear that they're open to it, … I would be like, yeah, here's how I take it and why."
	"I wouldn't say 'use', I would say 'consume'. [use] has a bit of a negative to it."
	"[marijuana] sometimes has a negative connotation, like it's a drug, but cannabis is more … like it's natural."
Theme 2a) Tool structure - General: The need for non-judgemental wording, and for cannabis to be treated separately from other substances on a questionnaire were identified as essential to avoid biased responses.	
	"Say something at the beginning to make it clear that you're not judging. If it sounds judgmental, or like, if I think you're asking me so you can lecture me … someone's judging me for using it, I wouldn't answer."
	"I feel like if doctors were a little non-judgmental and a little less biased, then it would create some more honesty."
	"If it's lumped in with, you know, smoking, then drinking, then marijuana, then …heroin and cocaine, that just gives it a real negative tone… like, it's worse than alcohol, and almost as bad as heroin… I wouldn't be answering, really, if it's like that."
	"it makes more sense to me to have it with… supplements, or alternative therapies."
Theme 2b) Tool structure - Response options: Allowing participants to indicate their reasons for consuming cannabis in pregnancy (which were predominantly reported as medicinal), was perceived as a key factor for encouraging honest disclosure. A response option indicating that use only took place prior to pregnancy recognition was also seen as essential to unbiased reporting.	
	"I believe the stigma has died a lot. But there is still a big stigma with pregnancy for some people."
	"Especially in the first pregnancy women feel a lot more judged."
	"I don't believe it should be used in pregnancy to get stoned, or to get high. But I believe that if it's going to help with morning sickness, or relieve pain, or anything that you're going through that may cause you suffering or stress, I believe it safe to use…"
	"some people stop as soon as they find out [they're pregnant], so you need to be able to say that."
Theme 3a) Patterns of use – Mode of consumption: Participants indicated numerous modes of consumption (vapour, oral/edible, topical, cannabidiol (CBD)) with varying doses for each, and some perceived as safer in pregnancy than others, supporting the need for standardized measurement of consumption-routes beyond smoking.	
	"I would think that ingesting it… would be a lot safer [than smoking] because there's less transfer to the fetus."
	"I think edibles and lotions and liquid CBD capsules even, they're most likely more safe to take during pregnancy considering just that you're taking out the smoking out of the equation"
	"I don't necessarily think that smoking it is the smartest."
	"I mostly smoke, but I have drops and a lotion too."
	"… for vaping it, [I] stick to three puffs maximum when it comes to THC products."
	"Smoking does work quite quickly, especially for morning sickness. But a tincture can work..."
	"I consume CBD oil daily, as well as smoking [cannabis]."
Theme 3b) Patterns of use – Frequency and Timing: Participants consistently indicated their patterns of use changed during pregnancy to a more frequent consumption of smaller amounts, compared to their general use pre-pregnancy, indicating that tool response options need to include high frequencies (i.e. multiple times per day) and small dose-per-use categories, compared to existing survey questions.	
	"I use it different (sic) now that I'm pregnant… I have a quick drag whenever I need it, so 3 or 4 times a day sometimes, but just a tiny bit, instead of having a lot at once."
	"…I resumed micro-dosing daily…"
	"I think asking about frequency makes sense - most people use it pretty regular (sic)"
Theme 3b) Patterns of use – Dose: Amounts of cannabis typically consumed at each sitting was discussed primarily in subjective terms (i.e. large, small), perceptions of which may vary considerably between consumers, and identifying the weights or exact doses used at each sitting was perceived as difficult or infeasible, particularly for dried cannabis. Comparison measures were preferred.	

	"I know how much I buy by weight, but I couldn't tell you the grams I put in the pipe yesterday evening..."
	"With smoking it, it's harder… like, a big joint for me might not be big for my sister."
	"It's easy if it's an edible, because it tells you on the label…"
	"The THC oil that I have is 30 milligrams per mil, so that would work out to being about point three milligrams for point one or point two of a milliliter."
	"Maybe start at half a milliliter, so that would be what? More like 10 milligrams, I guess, of the 40 milligram [per milliliter] stuff that I have."
	"I would say the easiest way for people to say how much they smoke would be like a pea-sized amount, or a grape-size…compare it to something. Then you could figure out the grams from that. I don't know how many grams or milligrams I use every time."
	"I might use a small dab like the size of a dime, or other times it might be like twice as much…"

Table 4: Concurrent validity of the CEPT vs. In-depth interview (*n=10)*

	Agreement		***Kappa***	***Std. Error***	***P-Value***
Construct	*actual*	*expected*			
Any use in pregnancy	100%	82%	1.00	0.31	>0.001
Frequency of use	90%	22%	0.87	0.16	>0.001
Timing (trimester)	80%	28%	0.72	0.19	>0.001
Mode of consumption	100%	22%	1.00	0.21	>0.001

Table 5: Discriminant validity of CEPT versus SUD screening tools (n=153)

	CEPT Agreement		***Kappa***	***Std. Error***	***P-Value***
Screening Tool	*actual*	*expected*			
5Ps	44.9%	45.1	-0.031	0.04	0.53
SURP-P	69.8%	52.3%	0.36	0.08	0.01

Legend: Compares positive SUD screening result with any prenatal cannabis use on CEPT

394 Table 6: Test-retest reliability of the CEPT - 3-month interval *(n=153)*

	Agreement		***Kappa***	***Std. Error***	***P-Value***
Construct	*actual*	*expected*			
Any second-hand exposure	92%	52%	0.83	0.08	>0.001
Any use in pregnancy	97%	51%	0.95	0.08	>0.001
Frequency of use	90%	28%	0.86	0.04	>0.001
Timing (trimester)	80%	32%	0.71	0.05	>0.001
Mode of consumption	99%	51%	0.97	0.08	>0.001

395

396 Table 7: Preliminary Validity of the CEPT against Biological THC

	Bioassay negative	**Bioassay positive**	**Total**
CEPT negative	8	4	12
*CEPT positive**	0	13	13
Total	8	17	**25**

Measure:		**95% confidence interval**
Sensitivity:	76.5%	59.84% - 93.10%
Specificity:	100%	100.00% - 100.00%
PPV:	100%	100.00% - 100.00%
NPV:	66.7%	48.19% - 85.15%

397 *positive prenatal exposure includes any cannabis use and/or second-hand exposure during pregnancy

398

399

Figure 1: Study Process Flow Diagram



403 Figure 2: Participant Characteristics Versus Maternal Population of Canada



404

405

406

Figure 3: Cognitive Interviews - Bias reduction for the five stages of cognition References:



411 1. Young-Wolff KC, Sarovar V, Tucker LY, Avalos LA, Alexeeff S, Conway A, et al. Trends in
412 marijuana use among pregnant women with and without nausea and vomiting in
413 pregnancy, 2009–2016. Drug Alcohol Depend. 2019;196:66–70.
414 2. Corsi DJ, Hsu H, Weiss D, Fell DB, Walker M. Trends and correlates of cannabis use in
415 pregnancy: a population-based study in Ontario, Canada from 2012 to 2017. Can J Public
416 Heal Can Sante Publique. 2018;Nov 1.
417 3. Luke S, Hutcheon J, Kendall T. Cannabis Use in Pregnancy in British Columbia and
418 Selected Birth Outcomes. J Obstet Gynaecol Canada. 2019;
419 4. Corsi DJ, Walsh L, Weiss D, Hsu H, El-Chaar D, Hawken S, et al. Association between Self-
420 reported Prenatal Cannabis Use and Maternal, Perinatal, and Neonatal Outcomes. JAMA
421 - J Am Med Assoc. 2019;
422 5. El Marroun H, Tiemeier H, Steegers EAP, Jaddoe VW V, Hofman A, Verhulst FC, et al.
423 Intrauterine Cannabis Exposure Affects Fetal Growth Trajectories: The Generation R
424 Study. J Am Acad Child Adolesc Psychiatry. 2009;48(12):1173–81.
425 6. Marroun H El, Hudziak JJ, Tiemeier H, Creemers H, Steegers EAP, Jaddoe VWV, et al.
426 Intrauterine cannabis exposure leads to more aggressive behavior and attention
427 problems in 18-month-old girls. Drug Alcohol Depend. 2011;
428 7. Stickrath E. Marijuana Use in Pregnancy: An Updated Look at Marijuana Use and Its
429 Impact on Pregnancy. Clin Obstet Gynecol. 2019;
430 8. Metz TD, Stickrath EH. Marijuana use in pregnancy and lactation: A review of the
431 evidence. Vol. 213, American Journal of Obstetrics and Gynecology. 2015. p. 761–78.
432 9. Porath-Waller AJ. Clearing the Smoke on Cannabis Series: Maternal Cannabis Use during

433 Pregnancy. Can Cent Subst Abus. 2015;1–8.

434 10. Board on Population Health and Public Health Practice, Health and Medicine Division,
435 National Academies of Sciences Engineering and Medicine. The Health Effects of
436 Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for
437 Research [Internet]. The Health Effects of Cannabis and Cannabinoids: The Current State
438 of Evidence and Recommendations for Research. 2017. 440 p. Available from:
439 http://www.ncbi.nlm.nih.gov/pubmed/28182367

440 11. Torres CA, Medina-Kirchner C, O'Malley KY, Hart CL. Totality of the Evidence Suggests
441 Prenatal Cannabis Exposure Does Not Lead to Cognitive Impairments: A Systematic and
442 Critical Review. Front Psychol. 2020;

443 12. Chaput KH, Lebel CA, McMorris CA. Commentary: Totality of the Evidence Suggests
444 Prenatal Cannabis Exposure Does Not Lead to Cognitive Impairments: A Systematic and
445 Critical Review. Front Psychol. 2020;tbd(e-pub).

446 13. Center for Behavioral Health Statistics and Quality. Results from the 2012 National
447 Survey on Drug Use and Health. 2013.

448 14. Roberts SCM, Nuru-Jeter A. Women's Perspectives on Screening for Alcohol and Drug
449 Use in Prenatal Care. Women's Heal Issues. 2010;20(3):193–200.

450 15. Ernhart CB, Morrow-Tlucak M, Sokol RJ, Martier S. Underreporting of alcohol use in
451 pregnancy. Alcohol Clin Exp Res. 1988;12(4):506–11.

452 16. Holland CL, Nkumsah MA, Morrison P, Tarr JA, Rubio D, Rodriguez KL, et al. "Anything
453 above marijuana takes priority": Obstetric providers' attitudes and counseling strategies
454 regarding perinatal marijuana use. Patient Educ Couns. 2016;99(9):1446–51.

455 17. Kaarid KP, Vu N, Bartlett K, Patel T, Sharma S, Honor RD, et al. Assessing the prevalence
456 and correlates of prenatal cannabis consumption in an urban Canadian population: a
457 cross-sectional survey. Can Med Assoc Open Access J [Internet]. 2021;9(2):E703--E710.
458 Available from: https://www.cmajopen.ca/content/9/2/E703
459 18. Chang JC, Holland CL, Tarr JA, Rubio D, Rodriguez KL, Kraemer KL, et al. Perinatal illicit
460 drug and marijuana use: An observational study examining prevalence, screening, and
461 disclosure. Am J Heal Promot. 2017;31(1):35–42.
462 19. Hannigan JH, Chiodo LM, Sokol RJ, Janisse J, Ager JW, Greenwald MK, et al. A 14-year
463 retrospective maternal report of alcohol consumption in pregnancy predicts pregnancy
464 and teen outcomes. Alcohol. 2010;44(7–8):583–94.
465 20. Chiodo LM, Sokol RJ, Delaney-Black V, Janisse J, Hannigan JH. Validity of the T-ACE in
466 pregnancy in predicting child outcome and risk drinking. Alcohol [Internet]. 2010/01/06.
467 2010;44(7–8):595–603. Available from: https://pubmed.ncbi.nlm.nih.gov/20053522
468 21. Rotermann M, Pagé MM. Prevalence and correlates of non-medical only compared to
469 self-defined medical and non-medical cannabis use, Canada, 2015. Heal Reports.
470 2018;29(7):3–13.
471 22. Singer LT, Arendt R, Fagan J, Minnes S, Salvator A, Bolek T, et al. Neonatal visual
472 information processing in cocaine-exposed and non-exposed infants. Infant Behav Dev.
473 1999;
474 23. Fried PA, Watkinson B. 36- and 48-month neurobehavioral follow-up of children
475 prenatally exposed to marijuana, cigarettes, and alcohol. J Dev Behav Pediatr. 1990;
476 24. Day NL, Richardson GA, Goldschmidt L, Robles N, Taylor PM, Stoffer DS, et al. Effect of

477 prenatal marijuana exposure on the cognitive development of offspring at age three.
478 Neurotoxicol Teratol. 1994;
479 25. el Marroun H, Tiemeier H, Jaddoe VWV, Hofman A, Mackenbach JP, Steegers EAP, et al.
480 Demographic, emotional and social determinants of cannabis use in early pregnancy: The
481 Generation R study. Drug Alcohol Depend. 2008;
482 26. Office of Research and Surveillance. Canadian Tobacco Alcohol and Drugs (CTADS): 2015
483 summary [Internet]. CTADS 2015. 2017. Available from:
484 https://www.canada.ca/en/health-canada/services/canadian-tobacco-alcohol-drugs-
485 survey/2015-summary.html
486 27. Coleman-Cowger VH, Schauer GL, Peters EN. Marijuana and tobacco co-use among a
487 nationally representative sample of US pregnant and non-pregnant women: 2005–2014
488 National Survey on Drug Use and Health findings. Drug Alcohol Depend. 2017;177.
489 28. Leos-Toro C, Rynard V, Hammond D. Prevalence of problematic cannabis use in Canada:
490 Cross-sectional findings from the 2013 Canadian Tobacco, alcohol and drugs survey. Can
491 J Public Heal. 2017;108(5–6):e516–22.
492 29. Gotman N, Kershaw T, Rounsaville BJ, Forray A, Howell HB, Yonkers KA. Screening for
493 Prenatal Substance Use. Obstet Gynecol. 2010;116(4):827–33.
494 30. Chasnoff IJ, Wells AM, McGourty RF, Bailey LK. Validation of the 4P's Plus© screen for
495 substance use in pregnancy validation of the 4P's Plus. J Perinatol. 2007;27(12):744–8.
496 31. Ondersma SJ, Svikis DS, Lebreton JM, Streiner DL, Grekin ER, Lam PK, et al. Development
497 and preliminary validation of an indirect screener for drug use in the perinatal period.
498 Addiction. 2012;107(12):2099–106.

499 32. Harris SK, Knight JR, Van Hook S, Sherritt L, L Brooks T, Kulig JW, et al. Adolescent
500 substance use screening in primary care: Validity of computer self-Administered versus
501 clinician-Administered screening. Subst Abus. 2016;37(1):197–203.
502 33. Yonkers KA, Gotman N, Kershaw T, Forray A, Howell HB, Rounsaville BJ. Screening for
503 prenatal substance use: Development of the substance use risk profile-pregnancy scale.
504 Obstet Gynecol. 2010;116(4):827–33.
505 34. James WH, Moore DD. Examining the Relationship between Gender and Drug-Using
506 Behaviors in Adolescents: The Use of Diagnostic Assessments and Biochemical Analyses
507 of Urine Samples. J Drug Educ. 2005;29(3):235–49.
508 35. Mura P, Kintz P, Papet Y, Ruesch G, Piriou A. [Evaluation of six rapid tests for screening of
509 cannabis in sweat, saliva and tears]. Acta Clin Belg. 1999;53 Suppl 1:35–8.
510 36. Pippins JR, Brawarsky P, Jackson RA, FuentesAfflick E, Haas JS. Association of
511 Breastfeeding with Maternal Depressive Symptoms. J Women's Heal [Internet]. 2006
512 Jul;15(6):754–62. Available from: http://Haas, Jennifer S.: jhaas@partners.org
513 37. Riley KJ, Lu NT, Taylor BG. Drug screening: A comparison of urinalysis results from two
514 independent laboratories. J Drug Issues. 2000;30(1):171–86.
515 38. Earleywine M. Understanding Marijuana: A New Look at the Scientific Evidence.
516 Understanding Marijuana: A New Look at the Scientific Evidence. 2010. 1–341 p.
517 39. Streiner DL, Norman GR. , John Cairney Health Measurement Scales: A Practical Guide To
518 Their Development and Use, January 2015 Edition: 5th Publisher: Oxford University Press
519 ISBN: 0199685215 DOI:10.1093/acprof:oso/9780199231881.003.0006,
520

521 40. Schwarz N, Oyserman D. Asking questions about behavior: Cognition, communication,
522 and questionnaire construction. Am J Eval. 2001;22(2):127–60.
523 41. Willis G, Lessler J. Question Appraisal System (QAS 99 Manual). 1999.
524 42. Coleman-Cowger VH, Oga EA, Peters EN, Trocin K, Koszowski B, Mark K. Comparison and
525 validation of screening tools for substance use in pregnancy: A cross-sectional study
526 conducted in Maryland prenatal clinics. BMJ Open. 2018;8(2).
527 43. Sale J, Brazil K. A strategy to identify critical appraisal criteria for primary mixed methods
528 research. Qual Quan. 2004;38:351–65.
529 44. Canada. PHA of. Data Tables - The Maternity Experiences Survey (MES) 2006 - 2007
530 [Internet]. Vol. 2012. 2009. Available from: http://www.phac-aspc.gc.ca/rhs-ssg/pdf/tab-
531 eng.pdf
532 45. Teubert D, Pinquart M, Pinheiro MIS, Haase VG, Del Prette A, Amarante CLD, et al. NIH
533 Public Access. Eur J Psychotraumatol [Internet]. 2015;15(1):No-Pagination Specified.
534 Available from: http://www.repositorio.ufc.br/bitstream/riufc/7744/1/2014-DIS-
535 ASMGRANGEIRO.pdf%0Ahttp://files/5407/GRANGEIRO,
536 2014.pdf%0Ahttp://files/5404/rocha, marina teses
537 ysr.pdf%0Ahttp://linkinghub.elsevier.com/retrieve/pii/S0890856716302167%0Ahttp://fil
538 es/5400/ache
539 46. No Title [Internet]. Vol. 2019. 2019. Available from:
540 https://www.nbs.go.tz/index.php/en/census-surveys/population-and-housing-
541 census/178-tanzania-total-population-by-district-regions-2016-2017
542 47. ElSohly MA, Mehmedic Z, Foster S, Gon C, Chandra S, Church JC. Changes in cannabis

543 potency over the last 2 decades (1995-2014): Analysis of current data in the United
544 States. Biol Psychiatry. 2016;
545 48. Niedbala S, Kardos K, Salamone S, Fritch D, Bronsgeest M, Cone EJ. Passive cannabis
546 smoke exposure and oral fluid testing. J Anal Toxicol. 2004;
547 49. Landis JR, Koch GG. The Measurement of Observer Agreement for Categorical Data.
548 Biometrics [Internet]. 1977 Jun 22;33(1):159–74. Available from:
549 http://www.jstor.org/stable/2529310
550 50. The National Academies of Science Engineering. The health effects of Cannabis and
551 Cannabinoids. Committee's conclusions. The National Academies of Science Engineering
552 and Medicine. Natl Acad Press [Internet]. 2018; Available from:
553 http://www.dictionary.com/browse/weight
554 51. Sokol RJ, Martier SS, Ager JW. The T-ACE questions: Practical prenatal detection of risk-
555 drinking. Am J Obstet Gynecol. 1989;160(4):863–70.
556 52. De Giovanni N, Fucci N. The Current Status of Sweat Testing For Drugs of Abuse: A
557 Review. Curr Med Chem. 2013;20(4):545–61.
558 53. Berg M. Status of research on gender differences in pharmacokinetics. J Am Pharm
559 Assoc. 1997;37:43–56.
560 54. Harris R, Benet L, Schwartz J. Gender effects in pharmacokinetics and
561 pharmacodynamics. Drigs. 1995;50:222–39.
562 55. Mattison D, Malek A, Cistola C. Physiologic adaptations to pregnancy: Impact on
563 pharmacokinetics. In: Yaffe S, Aranda J, editors. Pediatric Pharmacology: Therapeutic
564 principles in practice. Philidelphia: W.B. Saunders; 1992. p. 81–96.

565 56. Amon I, Huller H. Dose-response relationship as a basis for choice of drugs in pregnancy
566 and for dosage calculation. In: Kuemmerle H, Brendel K, editors. Clinical pharmacology in
567 pregnancy: Funda- mentals and rational pharmacotherapy. Nwe York: Thieme-Stratton;
568 1984. p. 64–73.
569 57. Lincoln Y, Guba NJ. Naturalistic inquiry. Vol. 1. Beverly Hills: Sage Publications; 1985.
570